MGS has launched the A.i.r. Platform, a new customizable auto-injector system designed to support flexible drug delivery development across multiple therapeutic areas.

The platform is built around an adaptable core engine that can be integrated into various device formats, with fill volumes ranging from 0.3 to 2.25 mL. MGS said A.i.r. allows companies to tailor devices across form, function, and aesthetics while incorporating patient-friendly features such as audible feedback, adjustable injection times and compatibility with different drug viscosities.

Bob Bordignon, svp of sales and marketing at MGS, said: “The A.i.r. Platform represents a major leap forward in how auto-injectors are developed, customized and scaled. This is exactly the kind of innovation our customers and their patients have been waiting for: flexible, efficient and built to meet the diverse needs of multiple patient groups.” He added that MGS’ experience delivering unique designs and manufacturing millions of auto-injector sub-assemblies informed the development of the platform.

The platform was created using insights from 14 therapeutic areas and incorporates feedback from clinicians, patients, regulatory guidance and FDA data. MGS said A.i.r. addresses common challenges seen with existing auto-injectors, including incomplete injections, activation failures and usability barriers, and can support lower manufacturing volumes where required. Features include specification of cap release, brand identification, patient usability optimisation, and simplified assembly with just seven plastic parts and two springs.

Martin Hoier Thomsen, senior development engineer and project manager at MGS, said: “The A.i.r. Platform is the result of years of discovery, engineering and collaborative design and development expertise. It was created to give customers access to more customization, advanced features and greater flexibility to meet a diverse range of patient needs, including pediatric-focused designs and solutions for users with limited dexterity due to chronic conditions. Pharma companies with drugs in development that require unique delivery solutions can avoid starting from scratch and save years of development time to reduce time to clinic.”

MGS emphasised that A.i.r. benefits from its end-to-end CDMO capabilities, providing design, development, tooling, automation and manufacturing support. The company said this integrated approach enables faster, more efficient delivery of combination products while maintaining quality and supporting sustainability goals.

Bordignon added: “We say we’re more than manufacturers, more than consultants – we’re end-to-end partners. What that means is that we’re in it with you to provide the agility, attention and focus you need to achieve your goals and accelerate your time to market. A.i.r. is an excellent representation of this end-to-end expertise, bringing knowledge together from each of our areas of discipline to produce a best-in-class device that will make a real impact on improving lives.”